Vabysmo Injection, Solution
Product Images NDC 50242-096

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Vabysmo (NDC 50242-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Faricimab 01)

An instructional illustration showing a hand holding a vial labeled with icons for eye, expiration date, and a drop, indicating usage for intravitreal injection. The image visually suggests checking the vial for these key identifiers before use.*

FDA Label Image

Figure B (Faricimab 02)

An instructional illustration showing proper vial handling for VABYSMO (faricimab) injection, solution, 6 mg/0.05 mL. It depicts pouring liquid from a tilted vial into another container on the left and an upright vial with a checkmark on the right, suggesting correct usage or preparation steps for the intravitreal injection.*

FDA Label Image

Figure C (Faricimab 03)

An instructional illustration showing a hand holding a syringe near a vial, with a close-up inset depicting liquid droplets being drawn from the vial into the syringe. The image demonstrates the preparation of an injectable medication, consistent with intravitreal injection procedures.*

FDA Label Image

Figure D (Faricimab 04)

Illustration shows a hand removing the cap from a vial, depicting a preparatory step for using an injectable solution. This relates generally to the handling or administration process of VABYSMO (Faricimab) injection, solution, intravitreal, 6 mg/0.05 mL by Genentech, Inc.*

FDA Label Image

Figure E (Faricimab 05)

An instructional illustration showing a hand pressing a swab or pad onto the top of a medication vial, likely demonstrating a step in preparing an injection. The image is a simple black-and-white line drawing without text.*

FDA Label Image

Figure F (Faricimab 06)

Instructional illustration showing how to remove the cap from a syringe filled with medication for injection. It depicts two hands holding the syringe and pulling the cap off by lifting and pulling it away.*

FDA Label Image

Figure G (Faricimab 07)

An instructional diagram depicting the preparation of an injection solution. The image shows a syringe positioned above a vial with an arrow indicating the syringe is to be inserted into the vial. This likely represents a step in preparing the VABYSMO (Faricimab) intravitreal injection solution for administration.*

FDA Label Image

Figure H (Faricimab 08)

An instructional illustration showing a syringe being used to draw liquid from a vial. A zoomed-in circular inset highlights a specific part of the syringe needle penetrating the vial stopper, emphasizing the proper technique for vial access.*

FDA Label Image

Figure I (Faricimab 09)

An instructional illustration showing the preparation of an intravitreal injection. The image depicts a hand holding a vial while a syringe is being drawn from it, emphasizing proper technique to withdraw medication, likely for VABYSMO (faricimab) injection, solution 6 mg/0.05 mL by Genentech, Inc.*

FDA Label Image

Figure J (Faricimab 10)

An instructional illustration showing a hand removing a needle cap from a syringe. The syringe contains a solution, presumably the injection dose, with a plunger and measurement markings visible. An arrow indicates the direction to pull the needle cap off from the syringe.*

FDA Label Image

Figure K (Faricimab 11)

An instructional illustration showing correct and incorrect ways to prepare a syringe for injection. The image highlights proper syringe plunger positioning, with a check mark indicating the correct method and an X indicating the incorrect method. It includes hands holding the syringe and a separate finger pointing to the syringe.*

FDA Label Image

Figure L (Faricimab 12)

An instructional diagram showing a hand holding a syringe labeled for injection with an enlarged inset highlighting a liquid measurement of 0.05 mL. The image visually demonstrates the correct volume to be drawn or administered for an intravitreal injection.*

FDA Label Image

Figure 1 (Faricimab 13)

A line graph comparing mean change in BCVA (ETDRS Letters) over 48 weeks for VABYSMO (6 mg faricimab) and Aflibercept injections, showing VABYSMO with a higher increase in BCVA than Aflibercept. The x-axis shows weeks (0 to 48); the y-axis shows mean change in BCVA. Data points for VABYSMO and Aflibercept are plotted with distinct markers and lines, with average changes at weeks 40, 44, and 48 indicated.*

FDA Label Image

Figure 2 (Faricimab 14)

A line graph comparing mean change in BCVA (ETDRS letters) over 48 weeks between VABYSMO (Faricimab) and Aflibercept. The x-axis shows weeks from 0 to 48, and the y-axis shows the mean change in BCVA from 0 to 8 letters. Two lines represent the treatments: VABYSMO with a black square marker and Aflibercept with a gray circle marker. Both treatments show a similar increase and plateau in mean change around week 36 to 48, with an average change of +6.6 letters at weeks 40, 44, and 48.*

FDA Label Image

Figure 3 (Faricimab 15)

The line graph depicts mean change in BCVA (ETDRS letters) over a 56-week period for three treatment groups: VABYSMO Variable (black squares), VABYSMO Q8W (gray triangles), and Aflibercept Q8W (light gray circles). The x-axis represents weeks, and the y-axis shows mean BCVA improvement, with VABYSMO Variable showing slightly higher gains at week 56.*

FDA Label Image

Figure 4 (Faricimab 16)

Line graph depicting mean change in BCVA (ETDRS letters) over 56 weeks comparing VABYSMO Variable dosing, VABYSMO every 8 weeks (Q8W), and Aflibercept every 8 weeks (Q8W). The graph shows visual acuity improvements for all groups, with VABYSMO Q8W showing the highest mean change at week 56.*

FDA Label Image

Principal Display Panel (6 mg Vial Carton)

Label for VABYSMO (faricimab-svoa) injection, a human prescription drug by Genentech, Inc. The label indicates a 6 mg dose in 0.05 mL of 120 mg/mL solution for intravitreal injection, supplied as a single-dose vial with one transfer filter needle.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.